How Long Should You Stay on Wegovy? Milestones & Long-Term Use

Wegovy (semaglutide) is one of the most thoroughly studied prescription weight management treatments available. In the landmark STEP-1 clinical trial, adults taking 2.4mg semaglutide once weekly lost an average of 14.9% of their starting weight over 68 weeks (1). Because clinical trials measure outcomes over fixed windows, many patients ask how long they should stay on Wegovy — and what happens if they eventually stop.

Do you have to stay on Wegovy forever?

Obesity is a chronic, biologically regulated metabolic condition. Population health data show that roughly 3 in 10 adults live with obesity, and long-term observational studies indicate that only around 1 in 10 adults with obesity transition to a metabolically healthy non-obese weight without structured intervention (2,3).

Because appetite hormones and resting energy expenditure adapt after weight loss, clinical obesity guidelines treat GLP-1 medications as long-term therapy paired with balanced nutrition and physical activity (4). While the STEP-1 extension trial found that participants regained around two-thirds of their lost weight within one year of stopping, individual outcomes vary — especially when sustainable protein, nutrition, and strength habits are built during treatment (5).

How long should you stay on Wegovy?

Duration on Wegovy is a shared clinical decision between you and your prescriber based on your weight goals, cardiometabolic health, side-effect tolerability, and ongoing benefit-to-risk balance. Clinical guidance recommends reviewing progress after six months on your highest tolerated maintenance dose; if total weight loss is under 5% of baseline body weight, your clinician may discuss switching to an alternative therapy such as tirzepatide (4).

Long-term data from the SELECT trial followed patients taking semaglutide for up to 4 years, demonstrating sustained weight maintenance and cardiovascular risk reduction (6). Ongoing trials such as the REST study are also investigating gradual tapering protocols compared with abrupt discontinuation (7).

Key milestones to expect on Wegovy

Progress varies from person to person, but clinical studies outline a clear timeline across titration and maintenance:

Weeks 1–4 (0.25mg starting dose)

Everyone begins on the 0.25mg weekly introductory dose to allow the gut and central appetite pathways to adapt (8). Many patients notice quieter “food noise” and earlier fullness within the first few weeks, alongside mild transient nausea or fatigue.

Dose escalation steps (Weeks 5–16)

Common gastrointestinal symptoms occur most frequently during or shortly after dose increases, peaking around week 20 and declining steadily thereafter (9). By Week 12, steady fat loss is typically underway as doses approach therapeutic strengths (10).

Week 20 to Week 24 (5–6 months)

In a 60-week randomized trial of semaglutide 2.4mg, participants had achieved an average 9.7% body-weight reduction by week 20 (11). At the 6-month mark, your clinician confirms you have surpassed the 5% responder benchmark.

Week 68 and beyond

In STEP-1, patients reached an average 14.9% weight reduction at 68 weeks (10), transitioning from active weight loss into long-term metabolic maintenance.

Can I stay on a lower maintenance dose of Wegovy?

Yes. While 2.4mg weekly is the standard maintenance dose, you do not have to push to the maximum dose if a lower strength is working well or if 2.4mg causes persistent side effects (8). Clinical data show that maintaining on 1.7mg weekly achieved roughly 11.5% weight loss at 68 weeks, confirming substantial efficacy at sub-maximal doses (12).

When to stop Wegovy immediately

Never stop or taper Wegovy without speaking to your clinical care team, except in urgent medical situations. Treatment must be paused or stopped if you:

• Are pregnant, breastfeeding, or planning pregnancy within the next 2 months
• Experience signs of a severe allergic reaction (swelling of lips, tongue, or throat, or difficulty breathing)
• Develop severe, persistent upper abdominal pain radiating to the back (potential acute pancreatitis)

References

1. Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2023;70(1).
2. CDC/National Center for Health Statistics. National Health and Nutrition Examination Survey (NHANES) — adult weight status. 2026.
3. Bell JA, et al. The Natural Course of Healthy Obesity Over 20 Years. J Am Coll Cardiol. 2015;65(1):101–102.
4. U.S. Preventive Services Task Force. Screening for and management of obesity in adults. 2025.
5. Pedersen SD, et al. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ. 2025;197(27):E797–E809.
6. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine. 2024;30(7):2049–2057.
7. Yevusiak T, et al. Recovery effects after semaglutide termination – The REST trial protocol. PLoS One. 2026;21(7):e0354237.
8. U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information — posology & missed doses. 2026.
9. Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4mg. Diabetes Obes Metab. 2022;24(1).
10. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.
11. Tronieri JS, et al. Effects of semaglutide 2.4mg on appetite and energy intake. 2026.
12. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022.